| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Thomas J Wang | |
| P2860 | cites work | Prediction of Coronary Heart Disease Using Risk Factor Categories | Q22241923 |
| Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis | Q73881440 | ||
| Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index | Q79125172 | ||
| The limitations of risk factors as prognostic tools | Q79445507 | ||
| Benchmarks for the assessment of novel cardiovascular biomarkers | Q79837581 | ||
| An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study | Q79873289 | ||
| Coronary calcification improves cardiovascular risk prediction in the elderly | Q80357431 | ||
| Multiple biomarkers for predicting cardiovascular events: lessons learned | Q84170300 | ||
| Separating the contenders from the pretenders: competitive high-throughput biomarker screening in large population-based studies | Q84290920 | ||
| The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study | Q84738339 | ||
| No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. | Q46513410 | ||
| Polymorphisms associated with cholesterol and risk of cardiovascular events | Q46691746 | ||
| Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view | Q47437281 | ||
| Prevalence of conventional risk factors in patients with coronary heart disease | Q47677468 | ||
| N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population | Q48301396 | ||
| Genetic variants associated with Lp(a) lipoprotein level and coronary disease. | Q50572117 | ||
| The effect of including C-reactive protein in cardiovascular risk prediction models for women. | Q51797108 | ||
| What makes a good predictor?: the evidence applied to coronary artery calcium score. | Q51829443 | ||
| Quantification of coronary artery calcium using ultrafast computed tomography. | Q52867038 | ||
| How useful is computed tomography for screening for coronary artery disease? Screening for coronary artery disease with electron-beam computed tomography is not useful. | Q53557095 | ||
| Prevention Conference V : Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Noninvasive Tests of Atherosclerotic Burden : Writing Group III | Q56567994 | ||
| Coronary Calcium Score Improves Classification of Coronary Heart Disease Risk in the Elderly | Q57259857 | ||
| Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects | Q57563944 | ||
| Arterial Stiffness and Risk of Coronary Heart Disease and Stroke | Q57781936 | ||
| Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women | Q58920530 | ||
| Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association | Q22241929 | ||
| Coronary Calcification, Coronary Disease Risk Factors, C-Reactive Protein, and Atherosclerotic Cardiovascular Disease Events | Q22252406 | ||
| Coronary Artery Calcium Score Combined With Framingham Score for Risk Prediction in Asymptomatic Individuals | Q22252997 | ||
| N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease | Q24607043 | ||
| Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants | Q24645076 | ||
| A common allele on chromosome 9 associated with coronary heart disease | Q24647989 | ||
| Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease | Q24649709 | ||
| Genomewide association analysis of coronary artery disease | Q24658344 | ||
| A strategy to reduce cardiovascular disease by more than 80% | Q24679592 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies | Q28145420 | ||
| Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests | Q28189909 | ||
| Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 | ||
| Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation | Q28204445 | ||
| Problems of spectrum and bias in evaluating the efficacy of diagnostic tests | Q28275783 | ||
| Use of multiple biomarkers to improve the prediction of death from cardiovascular causes | Q28280099 | ||
| Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review | Q28755180 | ||
| The meaning and use of the area under a receiver operating characteristic (ROC) curve | Q29547182 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 | ||
| Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond | Q29614697 | ||
| C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women | Q29616306 | ||
| Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men | Q29619308 | ||
| Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials | Q29622947 | ||
| Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association | Q30434464 | ||
| Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis | Q30435137 | ||
| Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. | Q30475959 | ||
| Clinical trial designs for predictive marker validation in cancer treatment trials | Q33213015 | ||
| Arterial stiffness and cardiovascular events: the Framingham Heart Study | Q33720064 | ||
| Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies | Q33829154 | ||
| Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease | Q33997369 | ||
| Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. | Q34021492 | ||
| Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis | Q34100632 | ||
| Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis | Q34160359 | ||
| Cardiovascular risk prediction: basic concepts, current status, and future directions | Q37734007 | ||
| By Jove! What is a clinician to make of JUPITER? | Q37768304 | ||
| Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project | Q38416428 | ||
| Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). | Q38467359 | ||
| Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy | Q39645977 | ||
| Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study | Q40202569 | ||
| Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study | Q40220698 | ||
| Use and misuse of the receiver operating characteristic curve in risk prediction | Q40241086 | ||
| Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study | Q40308364 | ||
| Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population | Q40402572 | ||
| N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults | Q40432735 | ||
| Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G | Q40479587 | ||
| The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease | Q40561664 | ||
| Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. | Q40586289 | ||
| Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study | Q40649173 | ||
| Randomized phase III clinical trial designs for targeted agents | Q42165255 | ||
| Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study | Q42858853 | ||
| Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). | Q43224125 | ||
| C-reactive protein and coronary disease: is there a causal link? | Q43245383 | ||
| Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project | Q43509265 | ||
| Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease | Q43617306 | ||
| Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. | Q43683472 | ||
| Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation | Q43742848 | ||
| Major risk factors as antecedents of fatal and nonfatal coronary heart disease events | Q44556056 | ||
| Novel Risk Markers and Clinical Practice | Q44628516 | ||
| Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial | Q46065204 | ||
| Expanding the orbit of primary prevention--moving beyond JUPITER. | Q46255870 | ||
| Plasma natriuretic peptide levels and the risk of cardiovascular events and death | Q34298401 | ||
| C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease | Q34311841 | ||
| Biomarkers of cardiovascular disease: molecular basis and practical considerations | Q34526561 | ||
| Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study | Q34539702 | ||
| Coronary artery calcium score and risk classification for coronary heart disease prediction | Q34552221 | ||
| C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study | Q34552689 | ||
| Multiple biomarkers for the prediction of first major cardiovascular events and death | Q34593507 | ||
| ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundat | Q34604622 | ||
| Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis | Q34604937 | ||
| Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice | Q34641225 | ||
| Genetically elevated C-reactive protein and ischemic vascular disease | Q34868720 | ||
| Novel and conventional biomarkers for prediction of incident cardiovascular events in the community | Q34960396 | ||
| Can the polypill save the world from heart disease? | Q34973137 | ||
| Clinical and research applications of carotid intima-media thickness | Q34978576 | ||
| Elements of danger--the case of medical imaging. | Q34999737 | ||
| Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement | Q35006693 | ||
| Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force | Q35006699 | ||
| Extended-release niacin or ezetimibe and carotid intima-media thickness. | Q35013008 | ||
| Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis | Q35822510 | ||
| Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia | Q35963030 | ||
| NT-ProBNP: the mechanism behind the marker | Q36158176 | ||
| Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). | Q36914416 | ||
| Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery | Q37000120 | ||
| Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. | Q37069329 | ||
| The search for new cardiovascular biomarkers | Q37089739 | ||
| Biomarkers for cardiovascular disease: challenges and future directions | Q37166894 | ||
| New susceptibility locus for coronary artery disease on chromosome 3q22.3. | Q37225243 | ||
| The use of genomics in clinical trial design | Q37284262 | ||
| Statin therapy and risk of developing type 2 diabetes: a meta-analysis | Q37364976 | ||
| Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures | Q37435521 | ||
| C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force | Q37608837 | ||
| B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies | Q37633816 | ||
| The value of carotid intima-media thickness for predicting cardiovascular risk | Q37641573 | ||
| Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis | Q37719080 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| biomarker | Q864574 | ||
| P304 | page(s) | 551-565 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction | |
| P478 | volume | 123 |
| Q36176050 | A Systematic Review of Biomarkers and Risk of Incident Type 2 Diabetes: An Overview of Epidemiological, Prediction and Aetiological Research Literature |
| Q41083010 | ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. |
| Q35878289 | Acute coronary events |
| Q47872910 | Adipocytokines and the risk of ischemic stroke: the PRIME Study |
| Q26827147 | Advances in the epidemiology of heart failure and left ventricular remodeling |
| Q37279381 | Ageing effect on flicker-induced diameter changes in retinal microvessels of healthy individuals |
| Q34460820 | Antibody phage display assisted identification of junction plakoglobin as a potential biomarker for atherosclerosis |
| Q35043143 | Arterial Stiffness |
| Q92177448 | B-Type Cardiac Natriuretic Peptides in the Neonatal and Pediatric Intensive Care Units |
| Q38324210 | BNP in children with congenital cardiac disease: is there now sufficient evidence for its routine use? |
| Q37313946 | Biological markers of oxidative stress: Applications to cardiovascular research and practice |
| Q33927398 | Biomarkers and cardiovascular risk assessment for primary prevention: an update |
| Q38826375 | Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers |
| Q49691813 | Biomarkers of cardiovascular disease: contributions to risk prediction in individuals with diabetes |
| Q38269951 | Biomarkers, erectile dysfunction, and cardiovascular risk prediction: the latest of an evolving concept |
| Q44306455 | Cerebral microbleeds and the risk of mortality in the general population |
| Q35999015 | Chapter 12: systematic review of prognostic tests |
| Q64121532 | Circulating Chemerin Levels, but not the Polymorphisms, Predict the Long-Term Outcome of Angiographically Confirmed Coronary Artery Disease |
| Q26824026 | Classical and novel biomarkers for cardiovascular risk prediction in the United States |
| Q37241404 | Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. |
| Q91958377 | Combination of left ventricular reverse remodeling and brain natriuretic peptide level at one year after cardiac resynchronization therapy predicts long-term clinical outcome |
| Q35868793 | Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3) |
| Q35019922 | Consolidated and emerging inflammatory markers in coronary artery disease |
| Q53119636 | Diagnosis: Biomarkers of cardiovascular outcomes--bonanza or bias? |
| Q53316781 | Difference in carotid artery elasticity in subjects with different brachial artery kinetic of vasodilatation. |
| Q40551297 | Differential incremental value of ultrasound carotid intima-media thickness, carotid plaque, and cardiac calcium to predict angiographic coronary artery disease across Framingham risk score strata in the APRES multicentre study |
| Q48832604 | Distribution of circulating cardiac biomarkers in healthy children: from birth through adulthood. |
| Q30456007 | ESR statement on the stepwise development of imaging biomarkers |
| Q35889098 | Effects of paediatric HIV infection on childhood vasculature |
| Q58762112 | Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice |
| Q28258442 | Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials |
| Q26866396 | Genetics of coronary artery disease |
| Q26825851 | Genome-wide association studies of chronic kidney disease: what have we learned? |
| Q57216341 | High sodium intake and sodium to potassium ratio may be linked to subsequent increase in vascular damage in adults aged 40 years and older: the Korean multi-rural communities cohort (MRCohort) |
| Q57417389 | High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis |
| Q97588555 | Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor |
| Q57388692 | Identification of relevant biomarkers for type 2 diabetes |
| Q26865722 | Identifying novel biomarkers for cardiovascular disease risk prediction |
| Q37092447 | Impact of neutrophil-to-lymphocyte ratio on periprocedural myocardial infarction in patients undergoing non-urgent percutaneous coronary revascularisation |
| Q33628664 | Improved prediction of cardiovascular events in diabetic patients: Role of quantitative ultrasonic tissue characterization |
| Q26770167 | Improved prediction of complex diseases by common genetic markers: state of the art and further perspectives |
| Q88909731 | Interdisciplinary Models for Research and Clinical Endeavors in Genomic Medicine: A Scientific Statement From the American Heart Association |
| Q34130734 | Intima media thickness, pulse wave velocity, and flow mediated dilation |
| Q92969534 | Is the Carotid Intima-Media Thickness a Reliable Predictor of Future Cardiovascular Events? |
| Q38128195 | LOX-1, a new marker of risk and prognosis in coronary artery disease? |
| Q42372131 | Metabolic profiling-multitude of technologies with great research potential, but (when) will translation emerge? |
| Q35152158 | Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts |
| Q26991473 | Metabolomics and cardiovascular biomarker discovery |
| Q92569268 | Metabolomics and its application in the treatment of coronary heart disease with traditional Chinese medicine |
| Q53552847 | Methods to Assess Genetic Risk Prediction. |
| Q41819473 | Molecular imaging of atherosclerosis: clinical state-of-the-art |
| Q48225509 | Multimarker Analysis for New Biomarkers in Relation to Central Arterial Stiffness and Hemodynamics in a Chinese Community-Dwelling Population |
| Q40266203 | Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts |
| Q38837698 | Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: new challenges and perspectives. |
| Q52955572 | Neutrophil to Lymphocyte Ratio and the Extent of Coronary Artery Disease: Results From a Large Cohort Study. |
| Q35136650 | Noninvasive tests for the diagnostic evaluation of dyspnea among outpatients: the Multi-Ethnic Study of Atherosclerosis lung study |
| Q55384368 | Nontraditional Cardiovascular Biomarkers and Risk Factors: Rationale and Future Perspectives. |
| Q26779339 | Novel Methods for Pulse Wave Velocity Measurement |
| Q28088373 | Novel methodologies for biomarker discovery in atherosclerosis |
| Q41074638 | Optimizing clinical use of biomarkers in high-risk acute heart failure patients |
| Q36011635 | Oxidative stress, oxidative balance score, and hypertension among a racially diverse population |
| Q24273409 | Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants |
| Q36851584 | Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study |
| Q64120958 | Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry |
| Q40964410 | Prognostic value of positron emission tomography myocardial perfusion imaging beyond traditional cardiovascular risk factors: Systematic review and meta-analysis |
| Q87168701 | Pulse wave velocity correlates with aortic atherosclerosis assessed with transesophageal echocardiography |
| Q36699023 | Relation between leukocyte telomere length and incident coronary heart disease events (from the 1995 Canadian Nova Scotia Health Survey). |
| Q90588213 | Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary |
| Q50014948 | Risk prediction by non-invasive coronary imaging: we are not there yet! |
| Q37962460 | Role of C-reactive protein when prescribing a statin |
| Q35485630 | Screening for cardiovascular disease using age alone: reflections on a paper peer-reviewed as both 'radical' and 'unsurprising'. |
| Q47098394 | Significance of the thrombo-inflammatory status-based novel prognostic score as a useful predictor for in-hospital mortality of patients with type B acute aortic dissection. |
| Q36429637 | Soluble Urokinase Receptor and Chronic Kidney Disease. |
| Q38303192 | State of the art of immunoassay methods for B-type natriuretic peptides: An update. |
| Q40458672 | Subclinical pulmonary congestion is prevalent in nephrotic syndrome. |
| Q53365942 | Systemic circulatory influences on retinal microvascular function in middle-age individuals with low to moderate cardiovascular risk. |
| Q38160931 | Targeted quantitation of CVD-linked plasma proteins for biomarker verification and validation |
| Q38879246 | The search for efficient diagnostic and prognostic biomarkers of heart failure. |
| Q38806531 | The use of machine learning for the identification of peripheral artery disease and future mortality risk |
| Q26829746 | The year in non-ST-segment elevation acute coronary syndrome |
| Q38966208 | Three-dimensional printed models in congenital heart disease. |
| Q31082889 | Translational and emerging clinical applications of metabolomics in cardiovascular disease diagnosis and treatment |
| Q30486678 | Utility of Gene Expression Profiling Score Variability to Predict Clinical Events in Heart Transplant Recipients |
| Q37975897 | Vascular effects of glycoprotein130 ligands--part II: biomarkers and therapeutic targets |
Search more.